At the heart of COVID-19.
COVID-19
cardiovascular
heart
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
20
04
2020
accepted:
21
04
2020
pubmed:
6
5
2020
medline:
25
6
2020
entrez:
6
5
2020
Statut:
ppublish
Résumé
Coronavirus disease (COVID-19) first presented in Wuhan, Hubei province, China in December 2019. Since then, it has rapidly spread across the world, and is now formally considered a pandemic. The disease does not discriminate but increasing age and the presence of comorbidities are associated with severe form of the disease and poor outcomes. Although the prevalence of COVID-19 in patients with cardiovascular disease is under-reported, there is evidence that pre-existing cardiac disease can render individuals vulnerable. It is thought that COVID-19 may have both a direct and indirect effect on the cardiovascular system; however, the primary mechanism of underlying cardiovascular involvement is still uncertain. Of particular interest is the role of angiotensin-converting enzyme 2, which is well known for its cardiovascular effects and is also considered to be important in the pathogenesis of COVID-19. With a range of different drug candidates being suggested, effective anti-virals and vaccines are an area of on-going research. While our knowledge of COVID-19 continues to rapidly expand, this review highlights recent advances in our understanding of the interaction between COVID-19 and the cardiovascular system.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1287-1294Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Ren L, Wang Y, Wu Z, et al. Identification of a novel coronavirus causing severe pneumonia in human. Chin Med J. 2020:1.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 12 April 2020.
Flahault A. Has China faced only a herald wave of SARS-CoV-2? The Lancet. 2020;395(10228):947.
Grech V. Unknown unknowns-COVID-19 and potential global mortality. Early Hum Dev. 2020;144:105026.
Bialek S, Boundy E, Bowen V, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346.
Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020:2000547.
Zheng Y, Ma Y, Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020.
Madjid M, Safavi-Naeini P, Solomon S, et al. Potential effects of coronaviruses on the cardiovascular system. JAMA Cardiol. 2020.
Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.
Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long Structural studies of SARS coronavirus. J Virol. 2020;94:7.
Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Med. 2005;11(8):875-879.
Kolifarhood G, Aghaali M, Saadati H, et al. Epidemiological and clinical aspects of COVID-19; a narrative review. Journals.sbmu.ac.ir. 2020. [Internet]. http://journals.sbmu.ac.ir/AAEM/index.php/AAEM/article/view/620. Accessed 11 April 2020.
Guan W, Ni H, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020.
World Health Organisation. Pneumonia of unknown cause-China. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed 11 April 2020.
World Health Organisation. Coronavirus disease 2019 (COVID-19) situation report-83 [Internet]. 2020. https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125. Accessed 12 April 2020.
Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020.
Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239.
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. JACC. 2020.
Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
Bonow RO, Fonarow GC, O'Gara PT, et al. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020.
Wu C, Postema P, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. 2020.
Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020.
Zeng JH, Liu Y-X, Yuan J, et al. First case of COVID-19 infection with fulminant myocarditis complication: case report and insights. Infection. 2020.
Chapman A, Adamson P, Mills N. Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart. 2016;103(1):10-18.
Oudit G, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618-625.
Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016;149(5):1294-1301.
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020.
Rivara M, Bajwa E, Januzzi J, et al. Prognostic significance of elevated cardiac troponin-T levels in acute respiratory distress syndrome patients. PLoS One. 2012;7(7):e40515.
Court O, Kumar A, Parrillo J, et al. Clinical review: myocardial depression in sepsis and septic shock. Crit Care. 2002;6(6):500.
Kochi A, Tagliari A, Forleo G, et al. Cardiac and arrhythmic complications in Covid-19 patients. J Cardiovasc Electrophysiol. 2020.
Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020.
Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the padua prediction score. J Thromb Haemost. 2010;8(11):2450-2457.
Xu J, Wang L, Zhao L, et al. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. Pulmonology. 2020.
Du R, Liang L, Yang C, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020:2000524
Fried J, Ramasubbu K, Bhatt R, et al. The variety of cardiovascular presentations of COVID-19. Circulation. 2020.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054-1062.
Beeching NFT, Fowler R. Coronavirus disease 2019 (COVID-19): BMJ best practice; 2020. https://bestpractice.bmj.com/topics/en-gb/3000168. Accessed 11 April 2020.
Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and Multi-Organ Response, Current Problems in Cardiology, 2020, https://doi.org/10.1016/j.cpcardiol.2020.100618
World Health Organisation. “Solidarity” clinical trial for COVID-19 treatments 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed 11 April 2020.
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci. 2020:202004168
Khashkhusha TR, Chan JSK, Harky A. ACE inhibitors and COVID-19: we don't know yet. J Card Surg. 2020. https://doi.org/10.1111/jocs.14582
European Society of Cardiology. Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers [Internet]. Escardio.org. 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. Accessed 12 April 2020.
Tam C, Cheung K, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020.
Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:1.